A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET)...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0221994 |
id |
doaj-6826e5d056cc437e95d2b64f908d0efe |
---|---|
record_format |
Article |
spelling |
doaj-6826e5d056cc437e95d2b64f908d0efe2021-03-03T21:12:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01149e022199410.1371/journal.pone.0221994A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.Edward WolinAlain MitaAmit MahipalTim MeyerJohanna BendellJohn NemunaitisPam N MunsterLuis Paz-AresEllen H FilvaroffShaoyi LiKristen HegeHans de HaanMonica MitaSecond-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET).Enrolled patients had metastatic, well-differentiated NET of non-pancreatic gastrointestinal or unknown origin, with/without carcinoid symptoms, had failed ≥1 systemic chemotherapy, and were taking a somatostatin analog (SSA). Oral once-daily CC-223 was administered in 28-day cycles starting at 45 mg (n = 24), with a subsequent cohort starting at 30 mg (n = 23). Objectives were to evaluate tolerability, preliminary efficacy, and pharmacokinetic and biomarker profiles of CC-223. Forty-seven patients completed the study, with mean treatment duration of 378 days and mean dose of 26 mg; 26% of patients remained on the starting dose. Most frequent grade ≥3 toxicities were diarrhea (38%), fatigue (21%), and stomatitis (11%). By investigator, 3 of 41 evaluable patients (7%) showed partial response (PR) and 34 (83%) had stable disease (SD) for a disease control rate (DCR) of 90% (95% confidence interval [CI] 76.9-97.3%). Duration of PR was 125-401 days; median SD duration was 297 days (min-max, 50-1519 days). Median progression-free survival was 19.5 months (95% CI 10.4-28.5 months). Carcinoid symptoms of flushing, diarrhea, or both improved in 50%, 41%, and 39% of affected patients, respectively. For the first time, this study describes that a second-generation mTOR pathway inhibitor can result in highly durable tumor regression and control of NET carcinoid symptoms. The manageable safety profile, high DCR, and durable response, coupled with reduction in carcinoid symptoms refractory to SSA, make CC-223 a promising agent for further development.https://doi.org/10.1371/journal.pone.0221994 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Edward Wolin Alain Mita Amit Mahipal Tim Meyer Johanna Bendell John Nemunaitis Pam N Munster Luis Paz-Ares Ellen H Filvaroff Shaoyi Li Kristen Hege Hans de Haan Monica Mita |
spellingShingle |
Edward Wolin Alain Mita Amit Mahipal Tim Meyer Johanna Bendell John Nemunaitis Pam N Munster Luis Paz-Ares Ellen H Filvaroff Shaoyi Li Kristen Hege Hans de Haan Monica Mita A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE |
author_facet |
Edward Wolin Alain Mita Amit Mahipal Tim Meyer Johanna Bendell John Nemunaitis Pam N Munster Luis Paz-Ares Ellen H Filvaroff Shaoyi Li Kristen Hege Hans de Haan Monica Mita |
author_sort |
Edward Wolin |
title |
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
title_short |
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
title_full |
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
title_fullStr |
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
title_full_unstemmed |
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
title_sort |
phase 2 study of an oral mtorc1/mtorc2 kinase inhibitor (cc-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET).Enrolled patients had metastatic, well-differentiated NET of non-pancreatic gastrointestinal or unknown origin, with/without carcinoid symptoms, had failed ≥1 systemic chemotherapy, and were taking a somatostatin analog (SSA). Oral once-daily CC-223 was administered in 28-day cycles starting at 45 mg (n = 24), with a subsequent cohort starting at 30 mg (n = 23). Objectives were to evaluate tolerability, preliminary efficacy, and pharmacokinetic and biomarker profiles of CC-223. Forty-seven patients completed the study, with mean treatment duration of 378 days and mean dose of 26 mg; 26% of patients remained on the starting dose. Most frequent grade ≥3 toxicities were diarrhea (38%), fatigue (21%), and stomatitis (11%). By investigator, 3 of 41 evaluable patients (7%) showed partial response (PR) and 34 (83%) had stable disease (SD) for a disease control rate (DCR) of 90% (95% confidence interval [CI] 76.9-97.3%). Duration of PR was 125-401 days; median SD duration was 297 days (min-max, 50-1519 days). Median progression-free survival was 19.5 months (95% CI 10.4-28.5 months). Carcinoid symptoms of flushing, diarrhea, or both improved in 50%, 41%, and 39% of affected patients, respectively. For the first time, this study describes that a second-generation mTOR pathway inhibitor can result in highly durable tumor regression and control of NET carcinoid symptoms. The manageable safety profile, high DCR, and durable response, coupled with reduction in carcinoid symptoms refractory to SSA, make CC-223 a promising agent for further development. |
url |
https://doi.org/10.1371/journal.pone.0221994 |
work_keys_str_mv |
AT edwardwolin aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT alainmita aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT amitmahipal aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT timmeyer aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT johannabendell aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT johnnemunaitis aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT pamnmunster aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT luispazares aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT ellenhfilvaroff aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT shaoyili aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT kristenhege aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT hansdehaan aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT monicamita aphase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT edwardwolin phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT alainmita phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT amitmahipal phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT timmeyer phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT johannabendell phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT johnnemunaitis phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT pamnmunster phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT luispazares phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT ellenhfilvaroff phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT shaoyili phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT kristenhege phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT hansdehaan phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms AT monicamita phase2studyofanoralmtorc1mtorc2kinaseinhibitorcc223fornonpancreaticneuroendocrinetumorswithorwithoutcarcinoidsymptoms |
_version_ |
1714818190206304256 |